{"version": "https://jsonfeed.org/version/1.1", "title": "Sharemaestro Newsreel: Brazil Biotechnology news", "home_page_url": "https://sharemaestro.com/newsreel/br/healthcare/biotechnology/", "feed_url": "https://sharemaestro.com/newsreel/br/healthcare/biotechnology/feed.json", "description": "Latest Biotechnology company headlines from Brazil, newest first, with source links and direct routes to company research and sentiment.", "language": "en", "items": [{"id": "source:8dc71079705610a28482643141072be9f4ca1d8b708f06563b733048af9fa884", "url": "https://finance.yahoo.com/healthcare/articles/biomarin-pharmaceutical-bmrn-outperforming-other-134002976.html", "external_url": "https://finance.yahoo.com/healthcare/articles/biomarin-pharmaceutical-bmrn-outperforming-other-134002976.html", "title": "Is BioMarin Pharmaceutical (BMRN) Outperforming Other Medical Stocks This Year?", "content_text": "Investors interested in Medical stocks should always be looking to find the best-performing companies in the group. Is BioMarin Pharmaceutical (BMRN) one of those stocks right now? A quick glance at the company's year-to-date performance in comparison to the rest of the Medical sector should help us answer this question. BioMarin Pharmaceutical is one of 914 individual stocks in the Medical sector. Collectively, these companies sit at #6 in the Zacks Sector Rank. The Zacks Sector Rank considers 16 different groups, measuring the average Zacks Rank of the individual stocks within the sector to ", "date_published": "2026-08-14T13:40:02+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Earnings", "B1MR34"], "_sharemaestro": {"country": "Brazil", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "B1MR34", "name": "BioMarin Pharmaceutical Inc.", "sentiment_url": "https://sharemaestro.com/sentiment/7a440876-d01c-4de4-9256-e2c68e30a51b/"}]}}, {"id": "source:eff5922e101371e66c6fa7e287bc65b5cf721f7fc28b7dab3b5aa6a295c6bcc3", "url": "https://finance.yahoo.com/markets/stocks/articles/zacks-com-featured-highlights-biomarin-093800634.html", "external_url": "https://finance.yahoo.com/markets/stocks/articles/zacks-com-featured-highlights-biomarin-093800634.html", "title": "Zacks.com featured highlights include BioMarin Pharmaceutical, Invesco, Centene Corporation, Hewlett Packard Enterprise and Gibraltar Industries", "content_text": "For Immediate Release Chicago, IL \u2013 August 14, 2026 \u2013 Stocks in this week's article are BioMarin Pharmaceutical BMRN, Invesco IVZ, Centene Corporation CNC, Hewlett Packard Enterprise HPE and Gibraltar Industries ROCK. 5 Undervalued Price-to-Book Stocks Worth Buying in August There are several different ways to find value stocks. Among these, the most popular are the price-to-earnings ratio (P/E) and the price-to-sales ratio (P/S). However, investors often overlook the price-to-book ratio (P/B ratio), which, though used less often, is also an easy-to-use valuation tool for identifying low-price", "date_published": "2026-08-14T09:38:00+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Market update", "B1MR34"], "_sharemaestro": {"country": "Brazil", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "B1MR34", "name": "BioMarin Pharmaceutical Inc.", "sentiment_url": "https://sharemaestro.com/sentiment/7a440876-d01c-4de4-9256-e2c68e30a51b/"}]}}, {"id": "source:483dae81a8645750f94d73ba0194dddd2330f8746335755914527985d64a5d07", "url": "https://seekingalpha.com/news/4633059-sp500-nasdaq-dow-jones-outlook-stock-market?amp%3Butm_medium=referral&amp%3Bfeed_item_type=news", "external_url": "https://seekingalpha.com/news/4633059-sp500-nasdaq-dow-jones-outlook-stock-market?amp%3Butm_medium=referral&amp%3Bfeed_item_type=news", "title": "Stock index futures largely flat after S&P 500 closes at record high", "content_text": "[Wall Street New York stock exchange stock market] alexsl Stock index futures were muted on Friday after the S&P 500 closed at a record high in the previous session. Dow futures (INDU [https://seekingalpha.com/symbol/INDU]) -0.12%, S&P 500 futures (SPX [https://seekingalpha.com/symbol/SPX]) +0.02%, and Nasdaq futures (US100:IND) -0.24%. The S&P 500 reached another intraday record on Thursday as investors weighed July producer prices, which showed wholesale inflation was unchanged from the previous month. Investors will turn to July retail sales data at 8:30 a.m. ET for fresh clues on consumer ", "date_published": "2026-08-14T08:11:29+00:00", "authors": [{"name": "seekingalpha.com"}], "tags": ["Macro sensitivity", "I1NC34"], "_sharemaestro": {"country": "Brazil", "coverage": "Provider-linked mention", "market_context": null, "companies": [{"symbol": "I1NC34", "name": "Incyte Corporation", "sentiment_url": "https://sharemaestro.com/sentiment/3b0b41b8-246b-4238-9e82-a53e88ebdba4/"}]}}, {"id": "source:59981c612ce15cd1484b2e39a59c6766da4145fe74d1a0ccab2a5ad215535de6", "url": "https://finance.yahoo.com/healthcare/articles/incyte-corporation-incy-bigger-revenue-000444398.html", "external_url": "https://finance.yahoo.com/healthcare/articles/incyte-corporation-incy-bigger-revenue-000444398.html", "title": "Incyte Corporation (INCY) has the Bigger Revenue Base, but Could Halozyme Therapeutics, Inc. (HALO) have the Better Economics?", "content_text": "On July 20, Halozyme Therapeutics, Inc. (NASDAQ:HALO) and Incyte Corporation (NASDAQ:INCY) announced a global collaboration and licensing deal to develop a subcutaneous formulation of Incyte's INCA033989. The first-in-class monoclonal antibody targets mutant calreticulin (mutCALR)-expressing myeloproliferative neoplasms. By utilizing Halozyme's proprietary ENHANZE drug delivery technology, INCY aims to create a more convenient dosing regimen for patients. HALO secures an upfront payment, milestone payments, and royalties on commercial sales, with Incyte holding an option to nominate two additi", "date_published": "2026-08-14T00:04:44+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Earnings", "I1NC34"], "_sharemaestro": {"country": "Brazil", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "I1NC34", "name": "Incyte Corporation", "sentiment_url": "https://sharemaestro.com/sentiment/3b0b41b8-246b-4238-9e82-a53e88ebdba4/"}]}}, {"id": "source:a48ab79e6d2911cf966c7ec605e452f2fa0e149f2592963120a961f03de7d20b", "url": "https://seekingalpha.com/news/4632646-s-and-p-500-tags-an-all-time-high-and-these-20-names-have-helped-fuel-the-rally?amp%3Butm_medium=referral&amp%3Bfeed_item_type=news", "external_url": "https://seekingalpha.com/news/4632646-s-and-p-500-tags-an-all-time-high-and-these-20-names-have-helped-fuel-the-rally?amp%3Butm_medium=referral&amp%3Bfeed_item_type=news", "title": "S&P 500 tags an all-time high and these 20 names have helped fuel the rally", "content_text": "[S&P Market Index Concept with Financial Graphs] AlexSecret The S&P 500 (SP500 [https://seekingalpha.com/symbol/SP500]) climbed to a fresh all-time high of 7,816.70 on Thursday, surpassing its prior record of 7,793.68 set on August 5. The benchmark advanced 0.6% for the session and is now up 13.5% year-to-date. Broad participation has supported the advance, with 350 of the index\u2019s 500 constituents trading higher in 2026. Leadership has been highly concentrated, however, as a select group of stocks has driven much of the gains. SanDisk Corp. has stood out at the forefront, soaring 559.7% year-t", "date_published": "2026-08-13T17:40:24+00:00", "authors": [{"name": "seekingalpha.com"}], "tags": ["Market update", "M1RN34"], "_sharemaestro": {"country": "Brazil", "coverage": "Provider-linked mention", "market_context": null, "companies": [{"symbol": "M1RN34", "name": "Moderna, Inc.", "sentiment_url": "https://sharemaestro.com/sentiment/e8a8abec-6856-4c97-9d97-a657c0ef4441/"}]}}, {"id": "source:c7625b0b19766561851dad85127678768ff68611e9ab773237c6ed514a1ff9ba", "url": "https://finance.yahoo.com/markets/stocks/articles/5-undervalued-price-book-stocks-132500956.html", "external_url": "https://finance.yahoo.com/markets/stocks/articles/5-undervalued-price-book-stocks-132500956.html", "title": "5 Undervalued Price-to-Book Stocks Worth Buying in August", "content_text": "There are several different ways to find value stocks. Among these, the most popular are the price-to-earnings ratio (P/E) and the price-to-sales ratio (P/S). However, investors often overlook the price-to-book ratio (P/B ratio), which, though used less often, is also an easy-to-use valuation tool for identifying low-priced stocks with great returns. The P/B ratio is calculated as below: P/B ratio = market capitalization/book value of equity This metric can help identify attractively priced stocks with upside potential. Some such stocks are BioMarin Pharmaceutical BMRN, Invesco IVZ, Centene Co", "date_published": "2026-08-13T13:25:00+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Earnings", "B1MR34"], "_sharemaestro": {"country": "Brazil", "coverage": "Provider-linked mention", "market_context": null, "companies": [{"symbol": "B1MR34", "name": "BioMarin Pharmaceutical Inc.", "sentiment_url": "https://sharemaestro.com/sentiment/7a440876-d01c-4de4-9256-e2c68e30a51b/"}]}}, {"id": "source:f4f0cfb1be75e5806057ed93225c6bd944ad0434bab79d80d251ca250823f59c", "url": "https://finance.yahoo.com/healthcare/articles/bio-techne-corrects-dividend-announcement-103000470.html", "external_url": "https://finance.yahoo.com/healthcare/articles/bio-techne-corrects-dividend-announcement-103000470.html", "title": "Bio-Techne Corrects Dividend Announcement", "content_text": "MINNEAPOLIS, Aug. 13, 2026 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) is issuing a correction to its dividend announcement released yesterday. The initial version incorrectly stated the shareholder of record date as August 17, 2026. The correct shareholder of record date is August 24, 2026. All other information contained in the dividend announcement remains unchanged. Bio-Techne Corporation announced that its Board of Directors has decided to pay a dividend of $0.08 per share for the quarter ended June 30, 2026. The quarterly dividend will be payable August 28, 2026, to all common ", "date_published": "2026-08-13T10:30:00+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Earnings", "T1CH34"], "_sharemaestro": {"country": "Brazil", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "T1CH34", "name": "Bio-Techne Corporation", "sentiment_url": "https://sharemaestro.com/sentiment/86977c03-7776-48b0-be7e-931154374cb2/"}]}}, {"id": "source:600ad22bd557ff450cdccc0f7657b5942d3c8ba776985e4725e313c0742a8287", "url": "https://finance.yahoo.com/healthcare/articles/beone-medicines-ltd-onc-q2-010458606.html", "external_url": "https://finance.yahoo.com/healthcare/articles/beone-medicines-ltd-onc-q2-010458606.html", "title": "BeOne Medicines Ltd (ONC) (Q2 2026) Earnings Call Highlights: Revenue Surges 30% to $1. ...", "content_text": "This article first appeared on GuruFocus. Total Revenue: $1.7 billion, representing 30% growth year over year. GAAP Earnings per ADS: $2.05, up 144% compared to the prior year. BRUKINSA Global Revenue: Over $1.2 billion, representing 31% year-over-year growth. US BRUKINSA Sales: $893 million, representing 31% growth. TEVIMBRA Global Sales: $229 million, representing 18% growth versus the prior period. Amgen In-Licensed Portfolio Revenue: $157 million, growing 25% year over year. US Revenue: Approximately $899 million, growing 31% year over year. China Revenue: Approximately $500 million, growi", "date_published": "2026-08-13T01:04:58+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Earnings", "B1ME34"], "_sharemaestro": {"country": "Brazil", "coverage": "Provider-linked mention", "market_context": null, "companies": [{"symbol": "B1ME34", "name": "BeOne Medicines AG", "sentiment_url": "https://sharemaestro.com/sentiment/38f3f13d-7f47-4ada-ac46-6622cf3252cf/"}]}}, {"id": "source:55c67ba2272dea5cc0cd1ede8ac29dbc25eda74abf99d734107491a87e3cb10b", "url": "https://finance.yahoo.com/markets/stocks/articles/bmrn-vs-ilmn-stock-better-154005188.html", "external_url": "https://finance.yahoo.com/markets/stocks/articles/bmrn-vs-ilmn-stock-better-154005188.html", "title": "BMRN vs. ILMN: Which Stock Is the Better Value Option?", "content_text": "Investors looking for stocks in the Medical - Biomedical and Genetics sector might want to consider either BioMarin Pharmaceutical (BMRN) or Illumina (ILMN). But which of these two companies is the best option for those looking for undervalued stocks? Let's take a closer look. We have found that the best way to discover great value opportunities is to pair a strong Zacks Rank with a great grade in the Value category of our Style Scores system. The proven Zacks Rank puts an emphasis on earnings estimates and estimate revisions, while our Style Scores work to identify stocks with specific traits", "date_published": "2026-08-12T15:40:05+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Earnings", "B1MR34"], "_sharemaestro": {"country": "Brazil", "coverage": "Provider-linked mention", "market_context": null, "companies": [{"symbol": "B1MR34", "name": "BioMarin Pharmaceutical Inc.", "sentiment_url": "https://sharemaestro.com/sentiment/7a440876-d01c-4de4-9256-e2c68e30a51b/"}]}}, {"id": "source:382c5f901b3fe24d52e18b823bbce0bd9ccc848d9b2a6c3a8e46d6d6e92c6cd4", "url": "https://finance.yahoo.com/healthcare/articles/biomarin-pharmaceutical-bmrn-stock-know-152522069.html", "external_url": "https://finance.yahoo.com/healthcare/articles/biomarin-pharmaceutical-bmrn-stock-know-152522069.html", "title": "BioMarin Pharmaceutical (BMRN) Stock Is Up, What You Need To Know", "content_text": "BioMarin Pharmaceutical (BMRN) Stock Is Up, What You Need To Know What Happened? Shares of biotech company BioMarin Pharmaceutical (NASDAQ:BMRN) jumped 2.6% in the morning session after an analyst at Canaccord Genuity raised the company's price target to $114 from $111 and maintained a \"Buy\" rating. The positive revision followed BioMarin's strong second-quarter 2026 earnings report. The company's revenue growth was driven by the addition of products from the recently closed Amicus acquisition. Following the strong results, BioMarin raised its fiscal 2026 guidance for total revenue, Voxzogo re", "date_published": "2026-08-12T15:25:22+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Earnings", "B1MR34"], "_sharemaestro": {"country": "Brazil", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "B1MR34", "name": "BioMarin Pharmaceutical Inc.", "sentiment_url": "https://sharemaestro.com/sentiment/7a440876-d01c-4de4-9256-e2c68e30a51b/"}]}}, {"id": "source:15cb90517d578b763e104c2e95c03c45b13caec26d6615a176e3914e9290a3ac", "url": "https://finance.yahoo.com/healthcare/articles/vertex-multiple-portfolio-catalysts-favorable-150252779.html", "external_url": "https://finance.yahoo.com/healthcare/articles/vertex-multiple-portfolio-catalysts-favorable-150252779.html", "title": "Vertex Has Multiple Portfolio Catalysts With Favorable Risk-Reward, RBC Says", "content_text": "Vertex Pharmaceuticals (VRTX) has multiple potential catalysts coming from its portfolio that provide a net positive risk-reward profile for the company, RBC Capital Markets said in a Wednesday note.The company is expected to present results from its phase 1 study of VX-828 in Silver Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium news articles. Upgrade now", "date_published": "2026-08-12T15:02:52+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Earnings", "VRTX34"], "_sharemaestro": {"country": "Brazil", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "VRTX34", "name": "Vertex Pharmaceuticals Incorporated", "sentiment_url": "https://sharemaestro.com/sentiment/439fe485-a409-46e2-a81f-f4bed6951fd5/"}]}}, {"id": "source:effa4ed1caf33496b3380870fdaa9fab5b585d707cfd898d9224cf86f7ba93bf", "url": "https://finance.yahoo.com/healthcare/articles/biomarin-targets-faster-deleveraging-amicus-140505463.html", "external_url": "https://finance.yahoo.com/healthcare/articles/biomarin-targets-faster-deleveraging-amicus-140505463.html", "title": "BioMarin Targets Faster Deleveraging as Amicus Deal Expands Rare-Disease Growth", "content_text": "Key Points Interested in BioMarin Pharmaceutical Inc.? Here are five stocks we like better. BioMarin raised its financial outlook after second-quarter revenue approached $1 billion, lifting 2025 revenue guidance to $3.875 billion\u2013$3.925 billion and non-GAAP EPS guidance to $4.90\u2013$5.10. The Amicus acquisition added Galafold and the Pombiliti/Opfolda Pompe franchise, with significant geographic expansion and diagnosis opportunities. BioMarin now expects to reduce leverage below 2.5 times by mid-next year, about a year ahead of its original target, while preserving Amicus' commercial capabilities", "date_published": "2026-08-12T14:05:05+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Earnings", "B1MR34"], "_sharemaestro": {"country": "Brazil", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "B1MR34", "name": "BioMarin Pharmaceutical Inc.", "sentiment_url": "https://sharemaestro.com/sentiment/7a440876-d01c-4de4-9256-e2c68e30a51b/"}]}}, {"id": "source:e4c1a669a5a0a41836bde78bb4549f530e9891b0c57a4a6e59051edf2ab0752b", "url": "https://finance.yahoo.com/markets/stocks/articles/wall-street-analysts-see-28-135501288.html", "external_url": "https://finance.yahoo.com/markets/stocks/articles/wall-street-analysts-see-28-135501288.html", "title": "Wall Street Analysts See a 28.2% Upside in BioMarin (BMRN): Can the Stock Really Move This High?", "content_text": "BioMarin Pharmaceutical (BMRN) closed the last trading session at $69.55, gaining 18.6% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall Street analysts are any guide. The mean price target of $89.16 indicates a 28.2% upside potential. The mean estimate comprises 25 short-term price targets with a standard deviation of $20.61. While the lowest estimate of $60.00 indicates a 13.7% decline from the current price level, the most optimistic analyst expects the stock to surge 78.3% to reach $124.00. It's very important to note t", "date_published": "2026-08-12T13:55:01+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Earnings", "B1MR34"], "_sharemaestro": {"country": "Brazil", "coverage": "Provider-linked mention", "market_context": null, "companies": [{"symbol": "B1MR34", "name": "BioMarin Pharmaceutical Inc.", "sentiment_url": "https://sharemaestro.com/sentiment/7a440876-d01c-4de4-9256-e2c68e30a51b/"}]}}, {"id": "source:46b3f23a3cbbf72aa4fa4eff600d629dac6ffd5d600b532526e1abeb25fd4333", "url": "https://seekingalpha.com/news/4631498-uk-regulator-reaffirms-safety-of-childhood-vaccination?amp%3Butm_medium=referral&amp%3Bfeed_item_type=news", "external_url": "https://seekingalpha.com/news/4631498-uk-regulator-reaffirms-safety-of-childhood-vaccination?amp%3Butm_medium=referral&amp%3Bfeed_item_type=news", "title": "U.K. regulator reaffirms safety of childhood vaccination", "content_text": "[Syringe drawing liquid medication from medical vial] zhikun sun/iStock via Getty Images Days after President Donald Trump ordered major changes to the U.S. childhood immunization schedule, the U.K. drug regulator on Wednesday reaffirmed the safety of pediatric vaccination, noting it remains one of the safest and most effective ways to fight many severe infectious diseases. Issuing an executive order to reduce the number of childhood vaccines administered in the U.S. and split the measles, mumps, and rubella vaccination into three separate shots on Monday, Trump suggested a link between vaccin", "date_published": "2026-08-12T13:13:40+00:00", "authors": [{"name": "seekingalpha.com"}], "tags": ["Market update", "B1NT34", "M1RN34"], "_sharemaestro": {"country": "Brazil", "coverage": "Provider-linked mention", "market_context": null, "companies": [{"symbol": "B1NT34", "name": "BioNTech SE", "sentiment_url": "https://sharemaestro.com/sentiment/b9eeaabe-1449-4413-8c51-24633cec2429/"}, {"symbol": "M1RN34", "name": "Moderna, Inc.", "sentiment_url": "https://sharemaestro.com/sentiment/e8a8abec-6856-4c97-9d97-a657c0ef4441/"}]}}, {"id": "source:c721d9481319c26b4b19076dda0a0430ca9ff56cd7115fd1a2d2b80702388820", "url": "https://finance.yahoo.com/markets/stocks/articles/4-outperforming-stocks-could-keep-120012403.html", "external_url": "https://finance.yahoo.com/markets/stocks/articles/4-outperforming-stocks-could-keep-120012403.html", "title": "4 Outperforming Stocks That Could Keep Rewarding Investors", "content_text": "The S&P 500 Index (SPX) is up about 13% on the year, and a surprising number of stocks have already doubled in value. Investors tend to get drawn to these high-flying stocks, which made me curious whether these stocks tend to keep going higher for the rest of the year or if they tend to give back some of their gains. In the article below, I dig into the historical data to determine if we can buy in now, or if it's too late. Stocks that Doubled vs. the Others For this study, I went back 10 years using the list of current S&P 500 stocks and found the stock's year-to-date return around this time ", "date_published": "2026-08-12T12:00:12+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Analyst action", "M1RN34"], "_sharemaestro": {"country": "Brazil", "coverage": "Provider-linked mention", "market_context": null, "companies": [{"symbol": "M1RN34", "name": "Moderna, Inc.", "sentiment_url": "https://sharemaestro.com/sentiment/e8a8abec-6856-4c97-9d97-a657c0ef4441/"}]}}, {"id": "source:66d3a20a42faf6505a6126b54c305ccc918667a7e7f3591aa3df56b21f0a49ec", "url": "https://www.nasdaq.com/articles/bio-techne-posts-q4-net-profit-expenses-drop-net-sales-improve", "external_url": "https://www.nasdaq.com/articles/bio-techne-posts-q4-net-profit-expenses-drop-net-sales-improve", "title": "Bio-Techne Posts Q4 Net Profit As Expenses Drop, Net Sales Improve", "content_text": "(RTTNews) - Bio-Techne Corporation (TECH), a provider of life science reagents, instruments, and services, on Wednesday reported net profit for the fourth quarter of fiscal 2026. For the three-month period to June 30, the company posted net profit of $54.622 million, or $0.35 per share, compared with net loss of $17.677 million, or $0.11 per share in the same period last year. Excluding items, earnings were $82.436 million, or $0.52 per share, less than $82.472 million, or $0.53 per share in the previous year. Operating income was $74.277 million as against loss of $23.860 million a year ago. ", "date_published": "2026-08-12T11:12:53+00:00", "authors": [{"name": "nasdaq.com"}], "tags": ["Earnings", "T1CH34"], "_sharemaestro": {"country": "Brazil", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "T1CH34", "name": "Bio-Techne Corporation", "sentiment_url": "https://sharemaestro.com/sentiment/86977c03-7776-48b0-be7e-931154374cb2/"}]}}, {"id": "source:77c9df0ffab0dcaff3034f70e888688fbcf314006ca5b7527e8fc365cf5026bf", "url": "https://finance.yahoo.com/healthcare/articles/one-company-clinical-miss-another-034131355.html", "external_url": "https://finance.yahoo.com/healthcare/articles/one-company-clinical-miss-another-034131355.html", "title": "One Company\u2019s Clinical Miss Is Another\u2019s Moat: Vertex Rallies as Sionna\u2019s CF Bet Collapses", "content_text": "Cystic fibrosis investors came to learn a harsh lesson on August 10 about how concentrated a market can be: Sionna Therapeutics, Inc. (NASDAQ:SION) shares fell more than 90% following a key trial failure, while Vertex Pharmaceuticals (NASDAQ:VRTX), the company whose drug dominance Sionna was attempting to challenge, surged to new highs. The Pipeline Flop Sionna Therapeutics, Inc. (NASDAQ:SION) announced the topline results of its Phase 2a \"PreciSION CF\" trial the morning of August 10, which tested its lead drug candidate SION-719 as a complementary therapy to Vertex's blockbuster Trikafta regimen. Beyond its primary safety goal, the trial's objective was to demonstrate that SION-719 could significantly increase CFTR protein function, measured via sweat chloride levels, over Trikafta alone. It didn't. The trial failed to meet its main activity endpoint, and Sionna Therapeutics, Inc. (NASDAQ:SION) has decided not to proceed SION-719 as a Trikafta add-on. The company noted some complicating aspects of the data, such as greater variability than anticipated in individual sweat chloride readings and inconsistent Trikafta exposure between treatment and placebo groups. That said, the bottom line for investors was clear: a well-funded challenger's leading clinical asset in CF had failed. Sionna Therapeutics, Inc. (NASDAQ:SION) wasn't completely wiped out on the day. A different, earlier-stage Phase 1 trial of its SION-451 combo program met its safety and pharmacokinetic targets, and the company says it will now prioritize that program instead. However, with over $268 million in cash and a lead program shelved, Sionna's stock reaction shows how much of its valuation was dependent on SION-719 succeeding. De-Risked Moat and Unrivaled Dominance For years, Vertex Pharmaceuticals (NASDAQ:VRTX) has enjoyed a near-monopoly in cystic fibrosis treatment, thanks to Trikafta and its successor Alyftrek. Given the extent of this dominance, any credible challenger's data has become a legitimate risk factor for the stock, with traders having openly cited Sionna's pipeline as an overhang on Vertex Pharmaceuticals (NASDAQ:VRTX), especially since a working NBD1 stabilizer could have harmed Trikafta's business. With the immediate threat removed, the market re-rated Vertex higher. That said, it's important to note that Vertex Pharmaceuticals (NASDAQ:VRTX) did not start from scratch. Shares were already up year-to-date, trading around record levels following a solid second quarter that included higher full-year revenue guidance and a proposed $10 billion acquisition of Crinetics Pharmaceuticals to expand into endocrinology. Story Continues Smart Money Sentiment Prior to the readout, smart money positions on Wall Street indicated two separate risk profiles. Insider Monkey's Q1 2026 data shows that hedge fund positions in Sionna Therapeutics, Inc. (NASDAQ:SION) increased from 23 in Q4 to 32 in Q1, as speculative investors positioned for a potential catalyst beat. However, this accumulation coincided with a significant 19.73% short interest rate, suggesting heavy institutional skepticism. Meanwhile, Vertex Pharmaceuticals (NASDAQ:VRTX) had strong institutional support with low short interest. Hedge fund ownership increased from 64 in the fourth quarter of the preceding year to 68 in the first quarter of 2026, while short interest was low at 1.97% of the float. Insider Monkey's Verdict The results are a reminder of Vertex Pharmaceuticals (NASDAQ:VRTX)'s status as the undisputed leader in cystic fibrosis. The healthcare giant remains a favorite institutional holding due to growing cash flows and a strategic push into endocrinology. Meanwhile, Sionna Therapeutics, Inc. (NASDAQ:SION) is morphing into a high-risk micro-cap restructurer where capital preservation and early-stage SION-451 data will determine any multi-year turnaround. While we acknowledge the potential of VRTX as an investment, we believe certain AI stocks offer greater upside potential and carry les", "date_published": "2026-08-12T03:41:31+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Market update", "VRTX34"], "_sharemaestro": {"country": "Brazil", "coverage": "Provider-linked mention", "market_context": null, "companies": [{"symbol": "VRTX34", "name": "Vertex Pharmaceuticals Incorporated", "sentiment_url": "https://sharemaestro.com/sentiment/439fe485-a409-46e2-a81f-f4bed6951fd5/"}]}}, {"id": "source:55a3270eab70bcb7bf8317e3b4c68cd08419056da1e9e96c4e285557febdbf61", "url": "https://finance.yahoo.com/healthcare/articles/5-insightful-analyst-questions-vertex-014122962.html", "external_url": "https://finance.yahoo.com/healthcare/articles/5-insightful-analyst-questions-vertex-014122962.html", "title": "5 Insightful Analyst Questions From Vertex Pharmaceuticals\u2019s Q2 Earnings Call", "content_text": "5 Insightful Analyst Questions From Vertex Pharmaceuticals's Q2 Earnings Call Vertex Pharmaceuticals' second quarter reflected strong commercial momentum, with management highlighting the performance of its cystic fibrosis (CF) portfolio and accelerating uptake of newer products like CASGEVY and JOURNAVX. CEO Reshma Kewalramani attributed revenue growth to \"the strength of our cystic fibrosis portfolio and the growing contributions from our newer products,\" while also emphasizing progress in regulatory and clinical milestones. Management specifically noted that ALYFTREK and TRIKAFTA continued to drive CF revenue, and that European launches benefitted from fewer monitoring requirements. Is now the time to buy VRTX? Find out in our full research report (it's free). Vertex Pharmaceuticals (VRTX) Q2 CY2026 Highlights: Revenue: $3.33 billion vs analyst estimates of $3.19 billion (12.5% year-on-year growth, 4.6% beat) Adjusted EPS: $4.73 vs analyst expectations of $4.75 (in line) Adjusted Operating Income: $1.42 billion vs analyst estimates of $1.37 billion (42.7% margin, 3.9% beat) The company slightly lifted its revenue guidance for the full year to $13.15 billion at the midpoint from $13.03 billion Operating Margin: 37.4%, down from 38.8% in the same quarter last year Market Capitalization: $125.7 billion While we enjoy listening to the management's commentary, our favorite part of earnings calls is the analyst questions. Those are unscripted and can often highlight topics that management teams would rather avoid or topics where the answer is complicated. Here is what has caught our attention. Our Top 5 Analyst Questions From Vertex Pharmaceuticals's Q2 Earnings Call Salveen Richter (Goldman Sachs): Asked about the Phase II/III OLYMPUS study dose selection for Pove in membranous nephropathy and bottlenecks in JOURNAVX's payer dynamics. CEO Reshma Kewalramani clarified the Data Safety Monitoring Board's role in dose selection and Duncan McKechnie highlighted ongoing efforts to secure broader access for JOURNAVX. Geoffrey Meacham (Citibank): Inquired about desired clinical outcomes for next-generation CF therapies and payer feedback on JOURNAVX in diabetic peripheral neuropathy. Kewalramani said efficacy and safety are the main goals, with further data and payer perspectives expected in coming quarters. Jessica Fye (JPMorgan): Asked about expected differentiation on eGFR endpoints for new IgAN treatments. Kewalramani explained that long-term benefits will depend on time to end-stage renal disease and the ability to achieve deeper reductions in proteinuria and hematuria. Cory Kasimov (Evercore ISI): Sought clarity on interim analysis criteria for inaxaplin in AMPLITUDE and accelerated approval. Kewalramani said the FDA agreement focuses on 1-year GFR as the primary endpoint for the interim analysis. Mohit Bansal (Wells Fargo): Queried prescription duration trends for JOURNAVX. McKechnie noted average durations have remained stable at around 10\u201311 days per prescription, split between hospital and retail settings. Story Continues Catalysts in Upcoming Quarters In coming quarters, the StockStory team will be watching (1) the pace of ALYFTREK adoption and label expansions in CF, (2) launch execution and patient uptake for CASGEVY and JOURNAVX, and (3) regulatory progress and launch timing for Pove in IgAN and the integration of Crinetics' assets. Progress in clinical data readouts for next-generation CF and renal assets will also be key signposts. Vertex Pharmaceuticals currently trades at $496.00, up from $470.72 just before the earnings. At this price, is it a buy or sell? Find out in our full research report (it's free for active Edge members). High-Quality Stocks for All Market Conditions ONE MORE THING: Top 5 Growth Stocks. The biggest stock winners almost always had one thing in common before they ran. Revenue growing like crazy. Meta. CrowdStrike. Broadcom. Our AI flagged all three. They returned 315%, 314%, and 455%, respectivel", "date_published": "2026-08-12T01:41:22+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Market update", "VRTX34"], "_sharemaestro": {"country": "Brazil", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "VRTX34", "name": "Vertex Pharmaceuticals Incorporated", "sentiment_url": "https://sharemaestro.com/sentiment/439fe485-a409-46e2-a81f-f4bed6951fd5/"}]}}, {"id": "source:64a311673a4275110c7f4979ead5a7faed1c0a8ff0cdfc3957387b4cc2c7dea5", "url": "https://finance.yahoo.com/healthcare/articles/hedge-funds-favor-argenx-argx-183557286.html", "external_url": "https://finance.yahoo.com/healthcare/articles/hedge-funds-favor-argenx-argx-183557286.html", "title": "Hedge Funds Favor argenx (ARGX) Over Forte Biosciences, Inc. (FBRX): Argenx Agrees to Buy Forte Biosciences", "content_text": "argenx SE (NASDAQ:ARGX) agreed to buy Forte Biosciences, Inc. (NASDAQ:FBRX) for about $2.2 billion in cash, paying $77 a share, a roughly 40% premium to Forte's Friday closing price. The deal adds Forte's experimental drug FB102, which analysts describe as a first-in-class anti-CD122 antibody, to Argenx's immunology pipeline. Both companies' boards have approved the deal, which the companies expect to close in the third quarter of 2026. Why Argenx Needs a Second Act argenx SE (NASDAQ:ARGX) has built its business almost entirely around one blockbuster drug, Vyvgart, which treats several autoimm", "date_published": "2026-08-11T18:35:57+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Earnings", "A1RG34"], "_sharemaestro": {"country": "Brazil", "coverage": "Provider-linked mention", "market_context": null, "companies": [{"symbol": "A1RG34", "name": "argenx SE", "sentiment_url": "https://sharemaestro.com/sentiment/7b4824ce-55f8-40c8-98dc-606ac2c33718/"}]}}, {"id": "source:b5c5f6effae20d31abd2fc458908d25a9a011a04c33fa24a80ba6b93393358e0", "url": "https://finance.yahoo.com/markets/stocks/articles/raymond-james-betting-big-2-175500329.html", "external_url": "https://finance.yahoo.com/markets/stocks/articles/raymond-james-betting-big-2-175500329.html", "title": "Raymond James Is Betting Big on These 2 \u2018Strong Buy\u2019 Stocks", "content_text": "The S&P 500 is now sitting just below its record high, with another strong earnings season helping stocks remain near their highs. The strength has not been limited to just a handful of companies either, with most S&P 500 sectors contributing to earnings growth during the current reporting season. Claim 55% Off TipRanks Unlock powerful investing tools with TipRanks Premium to make smarter, more confident investment decisions Subscribe to TipRanks Smart Investor Newsletter, and discover new investing opportunities with data-backed stock picks Larry Adam, CIO at Raymond James, has been watching ", "date_published": "2026-08-11T17:55:00+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Earnings", "A1LN34"], "_sharemaestro": {"country": "Brazil", "coverage": "Provider-linked mention", "market_context": null, "companies": [{"symbol": "A1LN34", "name": "Alnylam Pharmaceuticals, Inc.", "sentiment_url": "https://sharemaestro.com/sentiment/893d4251-3d49-4e3a-af6b-1d7821627ed2/"}]}}, {"id": "source:f7a30a89644c57d89e135fc152fadf8f6cf5fbb9c68c4262eefdd9b7f5f25ba5", "url": "https://finance.yahoo.com/markets/stocks/articles/argenx-enxtbr-argx-draws-fresh-161353432.html", "external_url": "https://finance.yahoo.com/markets/stocks/articles/argenx-enxtbr-argx-draws-fresh-161353432.html", "title": "argenx (ENXTBR:ARGX) Draws Fresh Valuation Debate, Is The Stock Overvalued Or Undervalued?", "content_text": "Never miss an important update on your stock portfolio and cut through the noise. Over 7 million investors trust Simply Wall St to stay informed where it matters for FREE. Recent share performance and business profile Without a single clear news event driving headlines, argenx (ENXTBR:ARGX) has still drawn attention after a recent move in its share price and steady gains over the past year. The stock last closed at \u20ac767, with returns around 0.5% over the past day and roughly 6% over the past week. Over the past month the move has been closer to flat, while the past 3 months show a gain of abou", "date_published": "2026-08-11T16:13:53+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Earnings", "A1RG34"], "_sharemaestro": {"country": "Brazil", "coverage": "Provider-linked mention", "market_context": null, "companies": [{"symbol": "A1RG34", "name": "argenx SE", "sentiment_url": "https://sharemaestro.com/sentiment/7b4824ce-55f8-40c8-98dc-606ac2c33718/"}]}}, {"id": "source:8dc753318c40bcc1666bbc6fb48d58022a30d0148989be9442b7bb88150302e2", "url": "https://finance.yahoo.com/markets/stocks/articles/mrk-stock-5-6-month-134800162.html", "external_url": "https://finance.yahoo.com/markets/stocks/articles/mrk-stock-5-6-month-134800162.html", "title": "MRK Stock Up 5.6% in a Month as Estimates Fall: Buy, Hold or Sell?", "content_text": "Merck's MRK stock is up 5.6% in a month. The key reason for the increase was the strong second-quarter 2026 performance. Merck beat estimates for both earnings and sales in the second quarter. Revenues in the second quarter increased 5% to $16.61 billion as higher sales of oncology drugs, including Keytruda, and contributions from new products like Winrevair, Welireg, and Capvaxive, and the Animal Health segment were partially offset by lower sales of Gardasil and some other vaccines. Sales of blockbuster PD-L1 inhibitor Keytruda increased 4% to $8.4 billion. Merck also raised its 2026 revenue", "date_published": "2026-08-11T13:48:00+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Earnings", "M1RN34"], "_sharemaestro": {"country": "Brazil", "coverage": "Provider-linked mention", "market_context": null, "companies": [{"symbol": "M1RN34", "name": "Moderna, Inc.", "sentiment_url": "https://sharemaestro.com/sentiment/e8a8abec-6856-4c97-9d97-a657c0ef4441/"}]}}, {"id": "source:85f600c286003b2872baa3897747d4fe35e679a79e531155df99048f818c2ef6", "url": "https://finance.yahoo.com/healthcare/articles/pfizer-inc-pfe-vs-biontech-123110407.html", "external_url": "https://finance.yahoo.com/healthcare/articles/pfizer-inc-pfe-vs-biontech-123110407.html", "title": "Pfizer Inc. (PFE) vs. BioNTech SE (BNTX): Which Pharma Giant Is Better Positioned for the Post-COVID Era?", "content_text": "Pfizer Inc. (NYSE:PFE) and BioNTech SE (NASDAQ:BNTX), two companies forever linked by their historic COVID-19 vaccine partnership, reported Q2 2026 earnings alongside major strategic announcements. While the European Commission authorized their updated XFG-adapted COVID-19 vaccine on July 29, the two partners are traveling down very different paths. One is leveraging massive scale and aggressive cost-cutting to protect profits, while the other is absorbing heavy losses to fund a corporate transition into oncology under new leadership.Pfizer vs. BioNTech: Which Pharma Giant Is Better Positioned", "date_published": "2026-08-11T12:31:10+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Earnings", "B1NT34"], "_sharemaestro": {"country": "Brazil", "coverage": "Provider-linked mention", "market_context": null, "companies": [{"symbol": "B1NT34", "name": "BioNTech SE", "sentiment_url": "https://sharemaestro.com/sentiment/b9eeaabe-1449-4413-8c51-24633cec2429/"}]}}, {"id": "source:64de25c2f0b03d23ec231b6756b869046803bacae8333fa1a1145a28592467d9", "url": "https://finance.yahoo.com/markets/stocks/articles/argenx-enxtbr-argx-stock-looks-111149889.html", "external_url": "https://finance.yahoo.com/markets/stocks/articles/argenx-enxtbr-argx-stock-looks-111149889.html", "title": "argenx (ENXTBR:ARGX) Stock Looks Fully Valued Despite Strong Returns And Deal Hopes", "content_text": "Make better investment decisions with Simply Wall St's easy, visual tools that give you a competitive edge. argenx stock has delivered a strong long term return over the past five years, yet the current valuation checks and recent acquisition plans raise questions about how much optimism is already reflected in the price. argenx has returned 193.8% over the past five years, which puts extra focus on whether recent gains are backed by enduring fundamentals rather than just momentum. The tender offer to acquire Forte Biosciences may support growth expectations if integration goes well. At the sa", "date_published": "2026-08-11T11:11:49+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Deals and strategy", "A1RG34"], "_sharemaestro": {"country": "Brazil", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "A1RG34", "name": "argenx SE", "sentiment_url": "https://sharemaestro.com/sentiment/7b4824ce-55f8-40c8-98dc-606ac2c33718/"}]}}, {"id": "source:087d578d3f75d830d50d54bbb4f31de98eb6f9576d94fb132b7fae0ab08fa04b", "url": "https://finance.yahoo.com/healthcare/articles/non-viral-transfection-reagents-market-084500474.html", "external_url": "https://finance.yahoo.com/healthcare/articles/non-viral-transfection-reagents-market-084500474.html", "title": "Non-Viral Transfection Reagents Market Report (3rd Edition) by Type of Non-Viral Transfection Method, Application Area, End-User & Region, Featuring Bio-Rad, MaxCyte, MilliporeSigma, Thermo Fisher Scientific", "content_text": "Company Logo Dublin, Aug. 11, 2026 (GLOBE NEWSWIRE) -- The \"Non-Viral Transfection Reagents Market (3rd Edition) by Type of Non-Viral Transfection Method, Application Area, End-User and Geographical Regions-Trends and Forecast Till 2035\" has been added to ResearchAndMarkets.com's offering. The global non-viral transfection reagents market is projected to increase from USD 0.89 billion in 2026 to USD 2.01 billion by 2035, expanding at a compound annual growth rate of 9.5% during the forecast period. Market growth is being driven by rising demand for nucleic acid-based therapeutics, continued in", "date_published": "2026-08-11T08:45:00+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Guidance", "M1RN34", "B1MR34"], "_sharemaestro": {"country": "Brazil", "coverage": "Provider-linked mention", "market_context": null, "companies": [{"symbol": "M1RN34", "name": "Moderna, Inc.", "sentiment_url": "https://sharemaestro.com/sentiment/e8a8abec-6856-4c97-9d97-a657c0ef4441/"}, {"symbol": "B1MR34", "name": "BioMarin Pharmaceutical Inc.", "sentiment_url": "https://sharemaestro.com/sentiment/7a440876-d01c-4de4-9256-e2c68e30a51b/"}]}}, {"id": "source:fafc61c50e634d6c45aecdb1952334394a1495194e5acc1d0607da1b1f8882e8", "url": "https://finance.yahoo.com/healthcare/articles/could-arbutus-biopharma-corporation-abus-001821145.html", "external_url": "https://finance.yahoo.com/healthcare/articles/could-arbutus-biopharma-corporation-abus-001821145.html", "title": "Could Arbutus Biopharma Corporation (ABUS) Turn its Moderna, Inc. (MRNA) Settlement Into a Lasting Biotech Advantage?", "content_text": "A landmark legal settlement in the biotech sector recently reshaped the financial trajectories of two key mRNA technology players: Arbutus Biopharma Corporation (NASDAQ:ABUS) and Moderna, Inc. (NASDAQ:MRNA). The resolution of their global patent infringement litigation over lipid nanoparticle (LNP) delivery technology provided Arbutus with a massive, non-dilutive liquidity boost while removing a significant overhang for Moderna as it seeks to expand its commercial pipeline beyond COVID-19.Could Arbutus Biopharma Corporation (ABUS) Turn Its Moderna, Inc. (MRNA) Settlement Into a Lasting Biotech", "date_published": "2026-08-11T00:18:21+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Earnings", "M1RN34"], "_sharemaestro": {"country": "Brazil", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "M1RN34", "name": "Moderna, Inc.", "sentiment_url": "https://sharemaestro.com/sentiment/e8a8abec-6856-4c97-9d97-a657c0ef4441/"}]}}, {"id": "source:af4ec5c8b52d2ee2a34db118d38a69c5eddfe684e0a78eb800d060f57f5b69c6", "url": "https://finance.yahoo.com/healthcare/articles/argenx-enxtbr-argx-considering-forte-221159692.html", "external_url": "https://finance.yahoo.com/healthcare/articles/argenx-enxtbr-argx-considering-forte-221159692.html", "title": "argenx (ENXTBR:ARGX) Is Considering A Forte Biosciences Acquisition", "content_text": "Track your investments for FREE with Simply Wall St, the portfolio command center trusted by over 7 million individual investors worldwide. argenx (ENXTBR:ARGX) is set to consider and discuss the acquisition of Forte Biosciences, Inc. The potential deal would expand argenx's reach in biopharmaceutical research and development. Management attention on the proposed acquisition could influence argenx's capital allocation priorities. Investors are watching for details on valuation terms and integration plans once disclosed. This kind of transaction is one part of a broader opportunity set in bioph", "date_published": "2026-08-10T22:11:59+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Deals and strategy", "A1RG34"], "_sharemaestro": {"country": "Brazil", "coverage": "Provider-linked mention", "market_context": null, "companies": [{"symbol": "A1RG34", "name": "argenx SE", "sentiment_url": "https://sharemaestro.com/sentiment/7b4824ce-55f8-40c8-98dc-606ac2c33718/"}]}}, {"id": "source:205b512e8b0ffa6bb8920650c9ec23803fc8fef84bfcc769bbff60e8e4060989", "url": "https://finance.yahoo.com/markets/stocks/articles/vertex-stock-jumps-5-9-155537840.html", "external_url": "https://finance.yahoo.com/markets/stocks/articles/vertex-stock-jumps-5-9-155537840.html", "title": "Vertex Stock Jumps 5.9% as Rival Cystic Fibrosis Drug Fails", "content_text": "This article first appeared on GuruFocus. Vertex Pharmaceuticals (NASDAQ:VRTX), the biotech king of cystic fibrosis, jumped approximately 5.9% in Monday's regular session after a rival drug stumbled. Sionna Therapeutics said SION-719 missed the key activity endpoint in a Phase 2a trial when added to the current standard of care. Sionna is now dropping that specific add-on strategy. That is a clean win for Vertex without Vertex doing anything. One potential challenger just lost momentum, giving its enormously profitable cystic-fibrosis franchise more breathing room. Warning! GuruFocus has detected 4 Warning Signs with VRTX. Is VRTX fairly valued? Test your thesis with our free DCF calculator. The Sionna's clinical update showed only a limited reduction in sweat chloride, an important measure of cystic-fibrosis transmembrane conductance regulator function. Sionna is investigating what went wrong and still has other drug combinations in development, so the competitive threat has not disappeared. But investors do not need every rival to disappear. They need Vertex's moat to stay wide. And right now, it is doing exactly that. Second-quarter revenue climbed 12% to roughly $3.33 billion, while management raised full-year revenue guidance to $13.1 billion$13.2 billion. The longer Vertex protects that cash machine, the more time it gets to build its next act across pain, kidney disease and gene editing.Vertex Stock Jumps 5.9% as Rival Cystic Fibrosis Drug Fails\u00b7us.finance.gurufocus Here is where the story gets even more interesting. GuruFocus puts Vertex's GF Value at $519.20, versus Monday's $526.15 share price. That means the stock trades only 1.34% above GF Value even after the 5.9% surge. In other words, Wall Street just handed Vertex a competitive gift, the stock popped, and the valuation still sits remarkably close to estimated fair value. Sionna's failure will not magically add billions to Vertex's revenue tomorrow. But investing is often about protecting what already works. Vertex owns the cystic-fibrosis throne. One challenger just took a step backward. And the market is suddenly putting a bigger price on that moat. View Comments", "date_published": "2026-08-10T15:55:37+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Market update", "VRTX34"], "_sharemaestro": {"country": "Brazil", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "VRTX34", "name": "Vertex Pharmaceuticals Incorporated", "sentiment_url": "https://sharemaestro.com/sentiment/439fe485-a409-46e2-a81f-f4bed6951fd5/"}]}}, {"id": "source:fa009c85a7fe13bb76c5bb7bbcf9d18fdf409b067d1f6cc4d2c1fd6d8a46c7ae", "url": "https://finance.yahoo.com/video/rocketlab-rises-space-interest-moderna-151617251.html", "external_url": "https://finance.yahoo.com/video/rocketlab-rises-space-interest-moderna-151617251.html", "title": "RocketLab Rises on Space Interest; Moderna Moves on Flu Shot | Stock Movers", "content_text": "On this episode of Stock Movers:- RocketLab (RKLB) shares are higher this morning after rising Friday, following earnings from SpaceX last week.- Moderna (MRNA) shares are moving after last week's news that its mRNA flu shot won US approval in an FDA turnaround.- Intel (INTC) shares are moving after the company said it will be offering $15 billion in common stock, taking advantage of renewed interest in its business prospects during the artificial intelligence data center boom. View Comments", "date_published": "2026-08-10T15:16:17+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Earnings", "M1RN34"], "_sharemaestro": {"country": "Brazil", "coverage": "Provider-linked mention", "market_context": null, "companies": [{"symbol": "M1RN34", "name": "Moderna, Inc.", "sentiment_url": "https://sharemaestro.com/sentiment/e8a8abec-6856-4c97-9d97-a657c0ef4441/"}]}}, {"id": "source:49be457c5beb197e8d56542c3cc33dd3537637da1ecb5fca8475f9aed49cd3d5", "url": "https://finance.yahoo.com/healthcare/articles/vertex-pharmaceuticals-vrtx-5-4-151413527.html", "external_url": "https://finance.yahoo.com/healthcare/articles/vertex-pharmaceuticals-vrtx-5-4-151413527.html", "title": "Vertex Pharmaceuticals (VRTX) Is Up 5.4% After Raising 2026 Revenue Guidance And Expanding Its Pipeline - Has The Bull Case Changed?", "content_text": "Vertex Pharmaceuticals recently reported second-quarter 2026 results, with revenue rising to US$3,333.9 million and net income reaching US$1,099.8 million, and raised its full-year 2026 revenue guidance to US$13.10\u2013US$13.20 billion. At the same time, a new collaboration with AbCellera on multispecific T\u2011cell engagers and a setback for a key cystic fibrosis competitor together highlight Vertex's efforts to broaden its pipeline while easing pressure on its core franchise. We'll now examine how Vertex's upgraded 2026 revenue guidance reshapes its existing investment narrative and the way investors may view future growth. Find 52 companies with promising cash flow potential yet trading below their fair value. Vertex Pharmaceuticals Investment Narrative Recap To own Vertex, you need to believe its cystic fibrosis engine can keep funding a broader portfolio in gene editing, pain and kidney disease, without margins slipping. The Q2 2026 beat and higher revenue guidance support that near term, while Sionna's cystic fibrosis setback temporarily eases competitive pressure. The key short term catalyst remains uptake of newer launches like CASGEVY and JOURNAVX, and the biggest risk is still how concentrated profits are in cystic fibrosis. The new AbCellera collaboration on multispecific T cell engagers fits directly into that diversification story, adding another potential pillar outside cystic fibrosis. It sits alongside ongoing CASGEVY label expansions and pain programs as part of the same catalyst: turning today's cash flows into a more balanced pipeline. How quickly these newer areas move from investment to meaningful revenue will shape how investors judge the upgraded US$13.10\u2013US$13.20 billion guidance in the context of future expectations. But while recent news may ease near term cystic fibrosis competition, investors should still be aware of how concentrated Vertex's profits remain... Read the full narrative on Vertex Pharmaceuticals (it's free!) Vertex Pharmaceuticals' narrative projects $17.2 billion revenue and $6.5 billion earnings by 2029. This requires 10.9% yearly revenue growth and about a $2.1 billion earnings increase from $4.4 billion today. Uncover how Vertex Pharmaceuticals' forecasts yield a $558.68 fair value, a 13% upside to its current price. Exploring Other PerspectivesVRTX 1-Year Stock Price Chart Some of the lowest ranked analysts were already assuming only about 6.8 percent annual revenue growth to roughly US$14.9 billion by 2029, so if you worry about pricing pressure and access constraints on high cost gene therapies, this new information could shift that more cautious story even further. Story Continues Explore 5 other fair value estimates on Vertex Pharmaceuticals - why the stock might be worth as much as 14% more than the current price! Reach Your Own Conclusion Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts. A great starting point for your Vertex Pharmaceuticals research is our analysis highlighting 3 key rewards that could impact your investment decision. Our free Vertex Pharmaceuticals research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Vertex Pharmaceuticals' overall financial health at a glance. Curious About Other Options? Early movers are already taking notice. See the stocks they're targeting before they've flown the coop: This technology could replace computers: discover 26 stocks that are working to make quantum computing a reality. Invest in the nuclear renaissance through our list of 89 elite nuclear energy infrastructure plays powering the global AI revolution. We've uncovered the 8 dividend fortresses yielding 5%+ that don't just survive market storms, but thrive in them. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology ", "date_published": "2026-08-10T15:14:13+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Market update", "VRTX34"], "_sharemaestro": {"country": "Brazil", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "VRTX34", "name": "Vertex Pharmaceuticals Incorporated", "sentiment_url": "https://sharemaestro.com/sentiment/439fe485-a409-46e2-a81f-f4bed6951fd5/"}]}}, {"id": "source:3f16e381edccce988bddb6050eea9b5366aedd1d7f2773abc046a7f3d8d04fa9", "url": "https://news.google.com/rss/articles/CBMivwFBVV95cUxOYUZQdDRDS0N6RzNZSjBtcURaWkstQjhldGx5eVE0NmhpV0J2cjY1WkVpaTNfN0l4aml5UTBpV3lkWU5IcjdUNXFmLXJzSjdwRlgwYllvR0JFeFFEazAyTm5Rc1hzd3gwd3BsMUQzblU5UFVFcVVMc3E1YXJZSm5KcmNoMm5mT0t2bnVvcXdld2M0ekU4UzhIc2tXcXhWS1c5QW1YaUIxVkRUNkctMGE3NXVDMHdudlVKVlhldlVrVQ?oc=5", "external_url": "https://news.google.com/rss/articles/CBMivwFBVV95cUxOYUZQdDRDS0N6RzNZSjBtcURaWkstQjhldGx5eVE0NmhpV0J2cjY1WkVpaTNfN0l4aml5UTBpV3lkWU5IcjdUNXFmLXJzSjdwRlgwYllvR0JFeFFEazAyTm5Rc1hzd3gwd3BsMUQzblU5UFVFcVVMc3E1YXJZSm5KcmNoMm5mT0t2bnVvcXdld2M0ekU4UzhIc2tXcXhWS1c5QW1YaUIxVkRUNkctMGE3NXVDMHdudlVKVlhldlVrVQ?oc=5", "title": "Bio-Techne enfrenta teste de resultados com acordo com a Merck pendente - Investing.com Brasil", "content_text": "Bio-Techne enfrenta teste de resultados com acordo com a Merck pendente - Investing.com Brasil", "date_published": "2026-08-10T14:27:00+00:00", "authors": [{"name": "Finan\u00e7as, C\u00e2mbio e Investimentos"}], "tags": ["Market update", "T1CH34"], "_sharemaestro": {"country": "Brazil", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "T1CH34", "name": "Bio-Techne Corporation", "sentiment_url": "https://sharemaestro.com/sentiment/86977c03-7776-48b0-be7e-931154374cb2/"}]}}, {"id": "source:d4a997611e99bc446034b28dc1f70a02e93aa3566bb24736a84a8d5453cff49e", "url": "https://finance.yahoo.com/m/228d5141-325a-32e3-b4da-3b347a2a5268/this-biotech%E2%80%99s-drug-could.html", "external_url": "https://finance.yahoo.com/m/228d5141-325a-32e3-b4da-3b347a2a5268/this-biotech%E2%80%99s-drug-could.html", "title": "This Biotech\u2019s Drug Could Treat Hot Flashes. The Stock Is Up 36% on Good News.", "content_text": "New data show a single dose of AbCellera\u2019s menopause treatment, ABCL635, reduces how often patients with menopause experience hot flashes. Continue Reading", "date_published": "2026-08-10T14:12:00+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Market update", "VRTX34"], "_sharemaestro": {"country": "Brazil", "coverage": "Provider-linked mention", "market_context": null, "companies": [{"symbol": "VRTX34", "name": "Vertex Pharmaceuticals Incorporated", "sentiment_url": "https://sharemaestro.com/sentiment/439fe485-a409-46e2-a81f-f4bed6951fd5/"}]}}, {"id": "source:465ba5a146eca7a17a9dddf98eb6236a85e588fd980e3cb89e4d06168ca9fb03", "url": "https://finance.yahoo.com/m/5448cf60-d94a-347d-90d3-c5b2cd4f502f/why-vertex-pharma-popped%2C-as.html", "external_url": "https://finance.yahoo.com/m/5448cf60-d94a-347d-90d3-c5b2cd4f502f/why-vertex-pharma-popped%2C-as.html", "title": "Why Vertex Pharma Popped, As A Key Rival Plummeted 90%", "content_text": "Vertex stock surged Monday after its competitor, Sionna Therapeutics, missed the mark for its highly anticipated cystic fibrosis treatment. Continue Reading", "date_published": "2026-08-10T13:22:53+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Market update", "VRTX34"], "_sharemaestro": {"country": "Brazil", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "VRTX34", "name": "Vertex Pharmaceuticals Incorporated", "sentiment_url": "https://sharemaestro.com/sentiment/439fe485-a409-46e2-a81f-f4bed6951fd5/"}]}}, {"id": "source:c108582154a7ac46f6f3a3b7763f7802d32a1c62db70017a6d2f9f5a2b91f7ac", "url": "https://finance.yahoo.com/healthcare/articles/pfizer-rises-almost-7-post-131700150.html", "external_url": "https://finance.yahoo.com/healthcare/articles/pfizer-rises-almost-7-post-131700150.html", "title": "Pfizer Rises Almost 7% Post Q2 Results: How to Play the Stock", "content_text": "Pfizer PFE stock has risen 6.9% since it announced second-quarter 2026 results on Aug. 4. Pfizer delivered a solid second quarter, beating estimates for both earnings and revenues. While earnings growth was flat year over year, revenues rose 1% on an operational basis. Strength in non-COVID products continued to offset declining sales of its COVID products, Comirnaty (COVID-19 vaccine - in partnership with BioNTech [BNTX]) and Paxlovid (oral antiviral). Excluding sales from BioNTech-partnered Comirnaty and Paxlovid, revenues increased 5% operationally. Pfizer also raised the lower end of its 2", "date_published": "2026-08-10T13:17:00+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Earnings", "B1NT34"], "_sharemaestro": {"country": "Brazil", "coverage": "Provider-linked mention", "market_context": null, "companies": [{"symbol": "B1NT34", "name": "BioNTech SE", "sentiment_url": "https://sharemaestro.com/sentiment/b9eeaabe-1449-4413-8c51-24633cec2429/"}]}}, {"id": "source:74366017fd2c0623307ac79147d5e34c80cb65bb87cd977037a35a42aa00bf8f", "url": "https://finance.yahoo.com/healthcare/articles/biomarin-participate-canaccord-genuity-46th-130500741.html", "external_url": "https://finance.yahoo.com/healthcare/articles/biomarin-participate-canaccord-genuity-46th-130500741.html", "title": "BioMarin to Participate at the Canaccord Genuity 46th Annual Growth Conference on Wednesday, August 12, 2026, at 8:00AM ET in Boston", "content_text": "SAN RAFAEL, Calif., Aug. 10, 2026 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced management will present at the Canaccord Genuity 46th Annual Growth Conference on Wednesday, August 12, 2026, at 8:00AM ET in Boston.BioMarin Pharmaceutical logo An audio webcast of the presentation will be available live. The webcast can be accessed at: https://investors.biomarin.com/. An archived version of the remarks will also be available through the Company's website for a limited time following the conference. About BioMarin BioMarin is a leading, global rare disease biotechnolo", "date_published": "2026-08-10T13:05:00+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Market update", "B1MR34"], "_sharemaestro": {"country": "Brazil", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "B1MR34", "name": "BioMarin Pharmaceutical Inc.", "sentiment_url": "https://sharemaestro.com/sentiment/7a440876-d01c-4de4-9256-e2c68e30a51b/"}]}}, {"id": "source:66ab8bfd34faa8655c2968caf9532358fbd7c0eb57ec2e654ef48ae347b1b679", "url": "https://news.google.com/rss/articles/CBMiakFVX3lxTFAxNWw2LTlRcWU1RUh5UDJDUmhzOVFUOTc4aEc0S0FOVWxYaUMwOUJTQTVYUnQwRm9fVTRBc0ptOXYzQmtDZENoUFpvRjhURjBJOHkybnRSTXhySTlBWVBmRkJaNGhBNk5jOUE?oc=5", "external_url": "https://news.google.com/rss/articles/CBMiakFVX3lxTFAxNWw2LTlRcWU1RUh5UDJDUmhzOVFUOTc4aEc0S0FOVWxYaUMwOUJTQTVYUnQwRm9fVTRBc0ptOXYzQmtDZENoUFpvRjhURjBJOHkybnRSTXhySTlBWVBmRkJaNGhBNk5jOUE?oc=5", "title": "An\u00e1lise e Previs\u00e3o das A\u00e7\u00f5es da Bio-Techne Corp (TECH)", "content_text": "An\u00e1lise e Previs\u00e3o das A\u00e7\u00f5es da Bio-Techne Corp (TECH)", "date_published": "2026-08-10T06:46:00+00:00", "authors": [{"name": "TradingKey"}], "tags": ["Market update", "T1CH34"], "_sharemaestro": {"country": "Brazil", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "T1CH34", "name": "Bio-Techne Corporation", "sentiment_url": "https://sharemaestro.com/sentiment/86977c03-7776-48b0-be7e-931154374cb2/"}]}}, {"id": "source:d68b0a1d48719cb431f473b25ba4d707fa326d03aa64ef0c19ecde50c7fe852e", "url": "https://www.globenewswire.com/news-release/2026/08/09/3341497/9788/en/bronstein-gewirtz-grossman-llc-urges-regeneron-pharmaceuticals-inc-investors-to-act-class-action-filed-alleging-investor-harm.html", "external_url": "https://www.globenewswire.com/news-release/2026/08/09/3341497/9788/en/bronstein-gewirtz-grossman-llc-urges-regeneron-pharmaceuticals-inc-investors-to-act-class-action-filed-alleging-investor-harm.html", "title": "Bronstein, Gewirtz & Grossman LLC Urges Regeneron Pharmaceuticals, Inc. Investors to Act: Class Action Filed Alleging Investor Harm", "content_text": "NEW YORK, Aug. 09, 2026 (GLOBE NEWSWIRE) -- Bronstein, Gewirtz & Grossman, LLC, a nationally recognized investor-rights law firm, announces that a class action lawsuit has been filed against Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and certain of its officers. This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Regeneron securities between August 1, 2025 and May 15, 2026, both dates inclusive (the \u201cClass Period\u201d). Such investors are encouraged to join this", "date_published": "2026-08-09T16:00:00+00:00", "authors": [{"name": "globenewswire.com"}], "tags": ["Regulatory and legal", "REGN34"], "_sharemaestro": {"country": "Brazil", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "REGN34", "name": "Regeneron Pharmaceuticals, Inc.", "sentiment_url": "https://sharemaestro.com/sentiment/d66f17b1-6450-4ef3-badc-733d31fbf551/"}]}}, {"id": "source:d57b5b18af87a6c4c97d2c4c28d98cf6f03ef2e7928b939a0fe59ecb5ec288c0", "url": "https://seekingalpha.com/news/4629554-notable-healthcare-headlines-for-the-week-eli-lilly-novo-nordisk-and-pfizer-in-focus?amp%3Butm_medium=referral&amp%3Bfeed_item_type=news", "external_url": "https://seekingalpha.com/news/4629554-notable-healthcare-headlines-for-the-week-eli-lilly-novo-nordisk-and-pfizer-in-focus?amp%3Butm_medium=referral&amp%3Bfeed_item_type=news", "title": "Notable healthcare headlines for the week: Eli Lilly, Novo Nordisk, and Pfizer in focus", "content_text": "Wall Street\u2019s major market averages ended higher on Friday after July's nonfarm payrolls surprised to the downside, showing an unexpected contraction in employment. The blue-chip Dow edged up 0.3%, the benchmark S&P 500 gained 0.62%, and the tech-focused Nasdaq Composite jumped 1.3%. The S&P 500 Health Care Index Sector (XLV [https://seekingalpha.com/symbol/XLV]) gained 1.92% during the week. The top S&P 500 healthcare gainers and losers for the last week are as follows: TOP GAINERS: Charles River Laboratories International (CRL [https://seekingalpha.com/symbol/CRL]) +15.04% Veeva Systems (VEE", "date_published": "2026-08-09T13:05:04+00:00", "authors": [{"name": "seekingalpha.com"}], "tags": ["Earnings", "M1RN34"], "_sharemaestro": {"country": "Brazil", "coverage": "Provider-linked mention", "market_context": null, "companies": [{"symbol": "M1RN34", "name": "Moderna, Inc.", "sentiment_url": "https://sharemaestro.com/sentiment/e8a8abec-6856-4c97-9d97-a657c0ef4441/"}]}}, {"id": "source:2668ba56fc8490dfdf15ee7d2ca8fb74a8b9a2a4ea525fbefdc9b370d1a7b91c", "url": "https://finance.yahoo.com/markets/stocks/articles/regeneron-pharmaceuticals-regn-keeps-buybacks-231155132.html", "external_url": "https://finance.yahoo.com/markets/stocks/articles/regeneron-pharmaceuticals-regn-keeps-buybacks-231155132.html", "title": "Regeneron Pharmaceuticals (REGN) Keeps Buybacks And Dividend In Focus As Fair Value Stays In Sight", "content_text": "Get insights on thousands of stocks from the global community of over 7 million individual investors at Simply Wall St. Dividend, earnings and buybacks in focus Regeneron Pharmaceuticals (REGN) has given investors several fresh data points to consider after confirming a quarterly dividend, releasing second quarter and half year 2026 results, and updating on recent share repurchases. See our latest analysis for Regeneron Pharmaceuticals. Alongside the latest dividend and earnings update, Regeneron Pharmaceuticals' recent share price return of 18.33% over 30 days and 9.72% over 90 days suggests ", "date_published": "2026-08-08T23:11:55+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Earnings", "REGN34"], "_sharemaestro": {"country": "Brazil", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "REGN34", "name": "Regeneron Pharmaceuticals, Inc.", "sentiment_url": "https://sharemaestro.com/sentiment/d66f17b1-6450-4ef3-badc-733d31fbf551/"}]}}, {"id": "source:e828472c5b24161f51db966f6e434179d811b0314022735c38d7054c6c345cca", "url": "https://news.google.com/rss/articles/CBMiZEFVX3lxTE1fUHJjbExROHlBT0FmM2JWTmhwUFoySzhEblU2Zm90cmF3bDhyZnlMMXBoY05ETWZrOEVGRXBpZHpmNVl2cm0yYS11VlV0NUJRNDh3NEYtVWhtakd1ZnM5bDllYXU?oc=5", "external_url": "https://news.google.com/rss/articles/CBMiZEFVX3lxTE1fUHJjbExROHlBT0FmM2JWTmhwUFoySzhEblU2Zm90cmF3bDhyZnlMMXBoY05ETWZrOEVGRXBpZHpmNVl2cm0yYS11VlV0NUJRNDh3NEYtVWhtakd1ZnM5bDllYXU?oc=5", "title": "Not\u00edcias das A\u00e7\u00f5es da Sarepta Therapeutics Inc (SRPT)", "content_text": "Not\u00edcias das A\u00e7\u00f5es da Sarepta Therapeutics Inc (SRPT)", "date_published": "2026-08-08T11:09:50+00:00", "authors": [{"name": "TradingKey"}], "tags": ["Market update", "S1RP34"], "_sharemaestro": {"country": "Brazil", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "S1RP34", "name": "Sarepta Therapeutics, Inc.", "sentiment_url": "https://sharemaestro.com/sentiment/d9197c4e-b923-4fa4-8b19-e13ac315e099/"}]}}, {"id": "source:44a49480a0d78fb881b7b4cf86099a861d84c09db7ce3fea2dc0a8a70ce52871", "url": "https://news.google.com/rss/articles/CBMiiwFBVV95cUxNWllrQWs0aTBTZzgyMnN1RE1rREtkY1Q3TzZSS3VOdzlCVEtvSTFHcy1LNmVDSEJ4WGJJZ29vNmI0czBEQWlIU2hTcVFqY19uNzM2YmJ3cWR3WWk1NkowQVFWVWI0OVhvQkdRazlyVi1meThqTEt4VE5femI5TDVuVlZUMmVQZ2JCQnJ3?oc=5", "external_url": "https://news.google.com/rss/articles/CBMiiwFBVV95cUxNWllrQWs0aTBTZzgyMnN1RE1rREtkY1Q3TzZSS3VOdzlCVEtvSTFHcy1LNmVDSEJ4WGJJZ29vNmI0czBEQWlIU2hTcVFqY19uNzM2YmJ3cWR3WWk1NkowQVFWVWI0OVhvQkdRazlyVi1meThqTEt4VE5femI5TDVuVlZUMmVQZ2JCQnJ3?oc=5", "title": "Demonstra\u00e7\u00e3o de Resultados de Bio-Techne Corp T1CH34", "content_text": "Demonstra\u00e7\u00e3o de Resultados de Bio-Techne Corp T1CH34", "date_published": "2026-08-08T09:48:36+00:00", "authors": [{"name": "ADVFN"}], "tags": ["Market update", "T1CH34"], "_sharemaestro": {"country": "Brazil", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "T1CH34", "name": "Bio-Techne Corporation", "sentiment_url": "https://sharemaestro.com/sentiment/86977c03-7776-48b0-be7e-931154374cb2/"}]}}, {"id": "source:3fcf42e74862140ef2f58fe62857cb979a6a80fed2d581e0edb35175dab4b669", "url": "https://news.google.com/rss/articles/CBMiakFVX3lxTE15cFhycmdxaEVEcXBfX25KdmNfQWFoUVEwN3NqY0xrVm9hQjVpeHhSQ2l0TG53RVdCWS1OQ2FkOTJmbURjZjBpalhLVkZtTjlDeUdwdGRjNVpTRC1mZEJGeDBUSHVyc0JxekE?oc=5", "external_url": "https://news.google.com/rss/articles/CBMiakFVX3lxTE15cFhycmdxaEVEcXBfX25KdmNfQWFoUVEwN3NqY0xrVm9hQjVpeHhSQ2l0TG53RVdCWS1OQ2FkOTJmbURjZjBpalhLVkZtTjlDeUdwdGRjNVpTRC1mZEJGeDBUSHVyc0JxekE?oc=5", "title": "Proje\u00e7\u00f5es de Resultados: Sarepta Therapeutics Inc (SRPT) \u2014 LPA e Crescimento de Receita", "content_text": "Proje\u00e7\u00f5es de Resultados: Sarepta Therapeutics Inc (SRPT) \u2014 LPA e Crescimento de Receita", "date_published": "2026-08-08T06:58:56+00:00", "authors": [{"name": "TradingKey"}], "tags": ["Market update", "S1RP34"], "_sharemaestro": {"country": "Brazil", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "S1RP34", "name": "Sarepta Therapeutics, Inc.", "sentiment_url": "https://sharemaestro.com/sentiment/d9197c4e-b923-4fa4-8b19-e13ac315e099/"}]}}, {"id": "source:8c2967a817d4b5440004ff317104d2ca6f0b04853c79555e2b24b110d05f58c0", "url": "https://www.nasdaq.com/articles/moderna-mrna-q2-2026-earnings-call-transcript", "external_url": "https://www.nasdaq.com/articles/moderna-mrna-q2-2026-earnings-call-transcript", "title": "Moderna (MRNA) Q2 2026 Earnings Call Transcript", "content_text": "Image source: The Motley Fool. DATE Friday, July 31, 2026 at 8:00 a.m. ET CALL PARTICIPANTS Chief Executive Officer - Stphane BancelPresident - Stephen HogeChief Financial Officer - James MockChief Development Officer - David Berman TAKEAWAYS Total Revenue -- $145 million, representing 2% growth driven by international strategic partnerships and stand-ready manufacturing revenue.Net Loss -- $782 million, an improvement of 5% compared to the prior year.Loss Per Share -- $1.97, improving from a loss of $2.13 in the second quarter of 2025.Cash and Investments -- $6.9 billion, a decrease from $7.5", "date_published": "2026-08-08T02:32:56+00:00", "authors": [{"name": "nasdaq.com"}], "tags": ["Earnings", "M1RN34"], "_sharemaestro": {"country": "Brazil", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "M1RN34", "name": "Moderna, Inc.", "sentiment_url": "https://sharemaestro.com/sentiment/e8a8abec-6856-4c97-9d97-a657c0ef4441/"}]}}, {"id": "source:14892a30ae99fde61b079d7117aff51c4a2791d3130279e3b2323b5c2523db00", "url": "https://finance.yahoo.com/healthcare/articles/biontech-bntx-brings-ceo-europe-231157680.html", "external_url": "https://finance.yahoo.com/healthcare/articles/biontech-bntx-brings-ceo-europe-231157680.html", "title": "BioNTech (BNTX) Brings In New CEO As Europe Clears Updated COVID 19 Shot", "content_text": "Never miss an important update on your stock portfolio and cut through the noise. Over 7 million investors trust Simply Wall St to stay informed where it matters for FREE. BioNTech (NasdaqGS:BNTX) named Dr. Guido Oelkers as incoming CEO, marking a major leadership transition at the company. The European Commission approved BioNTech's updated COVID-19 vaccine formula adapted for the XFG variant. The dual announcement links a change at the top with continued product development in COVID-19 vaccines. For readers looking to explore more stocks connected to the infrastructure behind this kind of va", "date_published": "2026-08-07T23:11:57+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Earnings", "B1NT34"], "_sharemaestro": {"country": "Brazil", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "B1NT34", "name": "BioNTech SE", "sentiment_url": "https://sharemaestro.com/sentiment/b9eeaabe-1449-4413-8c51-24633cec2429/"}]}}, {"id": "source:f7f83e02985b763ca30cf30b38dc1be358a1283ea11c459cb80c2ef475dc9b44", "url": "https://finance.yahoo.com/markets/stocks/articles/incyte-reports-inducement-grants-under-203000999.html", "external_url": "https://finance.yahoo.com/markets/stocks/articles/incyte-reports-inducement-grants-under-203000999.html", "title": "Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)", "content_text": "WILMINGTON, Del., August 07, 2026--(BUSINESS WIRE)--Incyte Corporation (Nasdaq: INCY) announced today that it granted restricted stock unit awards (RSUs) representing an aggregate of 21,556 shares of the Company's common stock and stock option awards to purchase an aggregate of 18,172 shares of the Company's common stock to 24 new employees. The awards were made under the Company's 2024 Inducement Stock Incentive Plan, with a grant date and vesting commencement date of August 3, 2026, and were approved by the compensation committee of the Company's board of directors as an inducement material ", "date_published": "2026-08-07T20:30:00+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Market update", "I1NC34"], "_sharemaestro": {"country": "Brazil", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "I1NC34", "name": "Incyte Corporation", "sentiment_url": "https://sharemaestro.com/sentiment/3b0b41b8-246b-4238-9e82-a53e88ebdba4/"}]}}, {"id": "source:492283d4d07290a6c7e6ffd8efc2a9a688b2492bb26c2d3e0eb38683f692835d", "url": "https://finance.yahoo.com/markets/stocks/articles/bio-techne-tech-above-fair-201419994.html", "external_url": "https://finance.yahoo.com/markets/stocks/articles/bio-techne-tech-above-fair-201419994.html", "title": "Is Bio-Techne (TECH) Above Fair Value After A 44% Return?", "content_text": "Get insights on thousands of stocks from the global community of over 7 million individual investors at Simply Wall St. Bio-Techne stock has delivered a strong 44.2% return over the past year, yet both its Discounted Cash Flow (DCF) intrinsic value estimate and market multiples currently point to the shares trading at a premium rather than as an obvious bargain. Over the last 12 months, Bio-Techne has returned 44.2%, which puts a clear spotlight on whether recent gains already reflect much of the good news in the price. Expectations around Bio-Techne's ability to grow revenue and sustain healt", "date_published": "2026-08-07T20:14:19+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Earnings", "T1CH34"], "_sharemaestro": {"country": "Brazil", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "T1CH34", "name": "Bio-Techne Corporation", "sentiment_url": "https://sharemaestro.com/sentiment/86977c03-7776-48b0-be7e-931154374cb2/"}]}}, {"id": "source:5c5be35755c8684b2a9f1d5c2bd76982f6de7275a6bf955361ed8f85a27effe7", "url": "https://news.google.com/rss/articles/CBMiZEFVX3lxTE5OZ0xSWXdJWURrV0ZHQkhpXzJra08wV2VacXZPTElFd01lQnRCUEQxVVlNTzAxdXM4TVlieHZsd0RaeDFLcVZDc1B6aVI2X083UEk0cllERHVUYUxUUmd4ZHR2bFc?oc=5", "external_url": "https://news.google.com/rss/articles/CBMiZEFVX3lxTE5OZ0xSWXdJWURrV0ZHQkhpXzJra08wV2VacXZPTElFd01lQnRCUEQxVVlNTzAxdXM4TVlieHZsd0RaeDFLcVZDc1B6aVI2X083UEk0cllERHVUYUxUUmd4ZHR2bFc?oc=5", "title": "Not\u00edcias das A\u00e7\u00f5es da BioMarin Pharmaceutical Inc (BMRN)", "content_text": "Not\u00edcias das A\u00e7\u00f5es da BioMarin Pharmaceutical Inc (BMRN)", "date_published": "2026-08-07T10:18:14+00:00", "authors": [{"name": "TradingKey"}], "tags": ["Market update", "B1MR34"], "_sharemaestro": {"country": "Brazil", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "B1MR34", "name": "BioMarin Pharmaceutical Inc.", "sentiment_url": "https://sharemaestro.com/sentiment/7a440876-d01c-4de4-9256-e2c68e30a51b/"}]}}, {"id": "source:d5d68171c1b7dc17e96cb31d8cbcb7169e17c9eeaa9313ee507fd149fdbb8f5a", "url": "https://news.google.com/rss/articles/CBMiakFVX3lxTFBFWWg4aTNfQm4tN29Od0lFX1A3X3paS1NFSTRXbVpKOHhYWHNzTW9oeFJENlQ0MkZkZERBbW54ZzJESS1LUmg0M21JcWlGOERraUtBLW1lRnVzallFZXFNNXVZUnNTM0JqeGc?oc=5", "external_url": "https://news.google.com/rss/articles/CBMiakFVX3lxTFBFWWg4aTNfQm4tN29Od0lFX1A3X3paS1NFSTRXbVpKOHhYWHNzTW9oeFJENlQ0MkZkZERBbW54ZzJESS1LUmg0M21JcWlGOERraUtBLW1lRnVzallFZXFNNXVZUnNTM0JqeGc?oc=5", "title": "Proje\u00e7\u00f5es de Resultados: Moderna Inc (MRNA) \u2014 LPA e Crescimento de Receita", "content_text": "Proje\u00e7\u00f5es de Resultados: Moderna Inc (MRNA) \u2014 LPA e Crescimento de Receita", "date_published": "2026-08-07T09:30:20+00:00", "authors": [{"name": "TradingKey"}], "tags": ["Market update", "M1RN34"], "_sharemaestro": {"country": "Brazil", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "M1RN34", "name": "Moderna, Inc.", "sentiment_url": "https://sharemaestro.com/sentiment/e8a8abec-6856-4c97-9d97-a657c0ef4441/"}]}}, {"id": "source:663bc64821459a9987cb5eb45351038e04219068c7282c82d0e7acda2ab4d6ee", "url": "https://news.google.com/rss/articles/CBMiugFBVV95cUxNSE9fTzc2eVAwYk9FV0t3bXNMZ20wd2hkVk9yQllHUUFacHBESmVnVWh1dXQ4WEs1T2pobDFFTjgzS3VDSjQxNkdsNHVYbGVBQ0Jwa3NkQ0ZmZWxSTjZFSDhQVGtYdzctTzFCRDVfRktlcld2ZTBJUEpaRWNqWGNzNzFGSUlYOWtFcXJDSkExeFYwT3pTc3R4ODZ0eHdnNlE1TVZQd1NrcDF2VHctLTljd19RanhNY09tQVE?oc=5", "external_url": "https://news.google.com/rss/articles/CBMiugFBVV95cUxNSE9fTzc2eVAwYk9FV0t3bXNMZ20wd2hkVk9yQllHUUFacHBESmVnVWh1dXQ4WEs1T2pobDFFTjgzS3VDSjQxNkdsNHVYbGVBQ0Jwa3NkQ0ZmZWxSTjZFSDhQVGtYdzctTzFCRDVfRktlcld2ZTBJUEpaRWNqWGNzNzFGSUlYOWtFcXJDSkExeFYwT3pTc3R4ODZ0eHdnNlE1TVZQd1NrcDF2VHctLTljd19RanhNY09tQVE?oc=5", "title": "As a\u00e7\u00f5es da Moderna sobem ligeiramente ap\u00f3s a empresa elevar a previs\u00e3o de receita", "content_text": "As a\u00e7\u00f5es da Moderna sobem ligeiramente ap\u00f3s a empresa elevar a previs\u00e3o de receita", "date_published": "2026-01-12T08:00:00+00:00", "authors": [{"name": "ADVFN"}], "tags": ["Market update", "M1RN34"], "_sharemaestro": {"country": "Brazil", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "M1RN34", "name": "Moderna, Inc.", "sentiment_url": "https://sharemaestro.com/sentiment/e8a8abec-6856-4c97-9d97-a657c0ef4441/"}]}}, {"id": "source:2f895d9d1672f507f762a0999f3b294a712dbe81d2237291426bfd441fe2107e", "url": "https://news.google.com/rss/articles/CBMijwFBVV95cUxQdmg3eGRlak1aRldBcVY5WV9zV2RvZ2x4bHAxajNkTXc3QVFFM2lxWHRkZ3lWWGhyRTFfa2JwRWNlMGpMc1JPeTBrSUhFYmRIM2kyWG5WdnAwLWliOUEycXM5dllralhVdldnQzF4dFdWb0JSc3N3Mm56Y3BzcnphNVNtRmNvOHlXeC1vTWU0QQ?oc=5", "external_url": "https://news.google.com/rss/articles/CBMijwFBVV95cUxQdmg3eGRlak1aRldBcVY5WV9zV2RvZ2x4bHAxajNkTXc3QVFFM2lxWHRkZ3lWWGhyRTFfa2JwRWNlMGpMc1JPeTBrSUhFYmRIM2kyWG5WdnAwLWliOUEycXM5dllralhVdldnQzF4dFdWb0JSc3N3Mm56Y3BzcnphNVNtRmNvOHlXeC1vTWU0QQ?oc=5", "title": "A previs\u00e3o sobre o pre\u00e7o das a\u00e7\u00f5es da Moderna para 2026, 2027, 2028\u20132030 e posteriores", "content_text": "A previs\u00e3o sobre o pre\u00e7o das a\u00e7\u00f5es da Moderna para 2026, 2027, 2028\u20132030 e posteriores", "date_published": "2025-08-28T07:00:00+00:00", "authors": [{"name": "LiteFinance"}], "tags": ["Market update", "M1RN34"], "_sharemaestro": {"country": "Brazil", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "M1RN34", "name": "Moderna, Inc.", "sentiment_url": "https://sharemaestro.com/sentiment/e8a8abec-6856-4c97-9d97-a657c0ef4441/"}]}}]}